Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRIL MALEATE versus MONOPRIL HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRIL MALEATE versus MONOPRIL HCT.
ENALAPRIL MALEATE vs MONOPRIL-HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril is a prodrug that is hydrolyzed to enalaprilat, a potent competitive inhibitor of angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium/water retention.
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing electrolyte and water excretion.
Initial: 5 mg orally once daily; titrate to 10-40 mg/day in 1-2 divided doses. Target: 10-40 mg/day. Maximum: 40 mg/day. Route: Oral. Frequency: Once or twice daily.
1 tablet (10-20 mg fosinopril / 12.5-25 mg hydrochlorothiazide) orally once daily; maximum dose 80 mg fosinopril / 50 mg hydrochlorothiazide per day.
None Documented
None Documented
Terminal elimination half-life of enalaprilat (active metabolite) is approximately 35-38 hours. This prolonged half-life supports once-daily dosing in most patients, but may require dosage adjustment in renal impairment.
Fosinoprilat: 11.5-12 h (terminal half-life extended in renal and hepatic impairment); hydrochlorothiazide: 5.6-14.8 h (varies with renal function).
Primarily renal (60-80% as unchanged drug and metabolites, mainly enalaprilat); biliary/fecal excretion accounts for the remainder (approximately 20-30%).
Fosinopril: renal (44%), biliary (46%); hydrochlorothiazide: renal (>95% as unchanged drug).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor/Diuretic Antihypertensive